Posted innews Oncology Otorhinolaryngology
Pembrolizumab Plus Quad-Shot Radiotherapy: A Promising Approach for Recurrent, Unresectable Head and Neck Cancer
A phase 2 trial shows pembrolizumab combined with low-dose quad-shot radiotherapy yields encouraging response rates and survival outcomes in recurrent, unresectable head and neck squamous cell carcinoma.